Top

Published in:

Open Access 01-12-2010 | Research article

Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival

Authors: David F Schaeffer, Daniel R Owen, Howard J Lim, Andrew K Buczkowski, Stephen W Chung, Charles H Scudamore, David G Huntsman, Sylvia SW Ng, David A Owen

Published in: BMC Cancer | Issue 1/2010

Abstract

Background

Pancreatic ductal adenocarcinoma is a lethal disease with a 5-year survival rate of 4% and typically presents in an advanced stage. In this setting, prognostic markers identifying the more agrressive tumors could aid in managment decisions. Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3, also known as IMP3 or KOC) is an oncofetal RNA-binding protein that regulates targets such as insulin-like growth factor-2 (IGF-2) and ACTB (beta-actin).

Methods

We evaluated the expression of IGF2BP3 by immunohistochemistry using a tissue microarray of 127 pancreatic ductal adenocarcinomas with tumor grade 1, 2 and 3 according to WHO criteria, and the prognostic value of IGF2BP3 expression.

Results

IGF2BP3 was found to be selectively overexpressed in pancreatic ductal adenocarcinoma tissues but not in benign pancreatic tissues. Nine (38%) patient samples of tumor grade 1 (n = 24) and 27 (44%) of tumor grade 2 (n = 61) showed expression of IGF2BP3. The highest rate of expression was seen in poorly differentiated specimen (grade 3, n = 42) with 26 (62%) positive samples. Overall survival was found to be significantly shorter in patients with IGF2BP3 expressing tumors (P = 0.024; RR 2.3, 95% CI 1.2-4.8).

Conclusions

Our data suggest that IGF2BP3 overexpression identifies a subset of pancreatic ductal adenocarcinomas with an extremely poor outcome and supports the rationale for developing therapies to target the IGF pathway in this cancer.

Available only for authorised users

Nielsen FC, Nielsen J, Christiansen J: A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand J Clin Lab Invest Suppl. 2001, 234: 93-9.CrossRefPubMed

Liao B, Patel M, Hu Y, Charles S, Herrick DJ, Brewer G: Targeted knockdown of the RNA-binding protein CRD-BP promotes cell proliferation via an insulin-like growth factor II-dependent pathway in human K562 leukemia cells. J Biol Chem. 2004, 279: 48716-24. 10.1074/jbc.M405853200.CrossRefPubMed

Ioannidis P, Mahaira LG, Perez SA, Gritzapis AD, Sotiropoulou PA, Kavalakis GJ, Antsaklis AI, Baxevanis CN, Papamichail M: CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells. J Biol Chem. 2005, 280: 20086-93. 10.1074/jbc.M410036200.CrossRefPubMed

Huttelmaier S, Zenklusen D, Lederer M, Dictenberg J, Lorenz M, Meng X, Bassell GJ, Condeelis J, Singer RH: Spatial regulation of beta-actin translation by Src-dependent phosphorylation of ZBP1. Nature. 2005, 438: 512-5. 10.1038/nature04115.CrossRefPubMed

Müeller-Pillasch F, Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H, Varga G, Friess H, Büchler M, Beger HG, Vila MR, Adler G, Gress TM: Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene. 1997, 14: 2729-33. 10.1038/sj.onc.1201110.CrossRefPubMed

Yaniv K, Yisraeli JK: The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene. 2002, 287: 49-54. 10.1016/S0378-1119(01)00866-6.CrossRefPubMed

Yisraeli JK: VICKZ proteins: a multi-talented family of regulatory RNA-binding proteins. Biol Cell. 2005, 97: 87-96. 10.1042/BC20040151.CrossRefPubMed

Mori H, Sakakibara S, Imai T, Nakamura Y, Iijima T, Suzuki A, Yuasa Y, Takeda M, Okano H: Expression of mouse igf2 mRNA-binding protein 3 and its implications for the developing central nervous system. J Neurosci Res. 2001, 64: 132-43. 10.1002/jnr.1060.CrossRefPubMed

Brants JR, Ayoubi TA, Chada K, Marchal K, Ven Van de WJ, Petit MM: Differential regulation of the insulin-like growth factor II mRNA-binding protein genes by architectural transcription factor HMGA2. FEBS Lett. 2004, 569: 277-83. 10.1016/j.febslet.2004.05.075.CrossRefPubMed

10.

Hammer NA, Hansen TO, Byskov AG, Rajpert-De Meyts E, Grøndahl ML, Bredkjaer HE, Wewer UM, Christiansen J, Nielsen FC: Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction. 2005, 130: 203-12. 10.1530/rep.1.00664.CrossRefPubMed

11.

Monk D, Bentley L, Beechey C, Hitchins M, Peters J, Preece MA, Stanier P, Moore GE: Characterisation of the growth regulating gene IMP3, a candidate for Silver-Russell syndrome. J Med Genet. 2002, 39: 575-81. 10.1136/jmg.39.8.575.CrossRefPubMedPubMedCentral

12.

Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C, Hameister H, Knöchel W, Adler G, Gress TM: Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev. 1999, 88: 95-9. 10.1016/S0925-4773(99)00160-4.CrossRefPubMed

13.

Wagner M, Kunsch S, Duerschmied D, Beil M, Adler G, Mueller F, Gress TM: Transgenic overexpression of the oncofetal RNA binding protein KOC leads to remodeling of the exocrine pancreas. Gastroenterology. 2003, 124: 1901-14. 10.1016/S0016-5085(03)00402-5.CrossRefPubMed

14.

Yantiss RK, Cosar E, Fischer AH: Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas. Acta Cytol. 2008, 52: 133-8.CrossRefPubMed

15.

Zhao H, Mandich D, Cartun RW, Ligato S: Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas. Diagn Cytopathol. 2007, 35: 700-4. 10.1002/dc.20739.CrossRefPubMed

16.

Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Hsieh CC, Li C, Chen W, Duan HO, McDougal S, Wu CL: Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 2006, 7: 556-64. 10.1016/S1470-2045(06)70732-X.CrossRefPubMed

17.

Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z, Kwon ED: External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 2008, 112: 1471-9. 10.1002/cncr.23296.CrossRefPubMedPubMedCentral

18.

Köbel M, Xu H, Bourne PA, Spaulding BO, Shih IeM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB: IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Modern Pathol. 2009, 22 (3): 469-75. 10.1038/modpathol.2008.206.CrossRef

19.

Lüttges J, Schemm S, Vogel I, Hedderich J, Kremer B, Klöppel G: The grade of pancreatic ductal adenocarcinomas is an independent prognostic factor and is superior to the immunohistochemical assessment of prolifertion. J Pathol. 2000, 154-161. 10.1002/(SICI)1096-9896(200006)191:2<154::AID-PATH603>3.0.CO;2-C. 191

20.

Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z: The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 2008, 32: 304-15. 10.1097/PAS.0b013e3181483ff8.CrossRefPubMed

21.

Köbel M, Weichert W, Crüwell K, Schmitt WD, Lautenschläger C, Hauptmann S: Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis. Virchows Arch. 2004, 445: 456-464. 10.1007/s00428-004-1095-0.CrossRefPubMed

22.

Liu CL, Montgomery KD, Natkunam Y, West RB, Nielsen TO, Cheang MC, Turbin DA, Marinelli RJ, Rijn van de M, Higgins JP: TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays. Mod Pathol. 2005, 18: 1641-1648.PubMed

23.

Xu H, Bourne PA, Spaulding BO, Wang HL: High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol. 2007, 38: 555-63. 10.1016/j.humpath.2006.11.011.CrossRefPubMed

24.

Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K: IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol. 2007, 20: 242-7. 10.1038/modpathol.3800735.CrossRefPubMed

25.

Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K, Mohanty S, Rock KL, Jiang Z: IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res. 2008, 14: 1701-6. 10.1158/1078-0432.CCR-07-2039.CrossRefPubMed

26.

Shiraishi K, Okita K, Kusano N, Harada T, Kondoh S, Okita S, Ryozawa S, Ohmura R, Noguchi T, Iida Y, Akiyama T, Oga A, Fukumoto Y, Furuya T, Kawauchi S, Sasaki KA: comparison of DNA copy number changes detected by comparative genomic hybridization in malignancies of the liver, biliary tract and pancreas. Oncology. 2001, 60 (2): 151-61. 10.1159/000055313.CrossRefPubMed

27.

Vikesaa J, Hansen TV, Jønson L, Borup R, Wewer UM, Christiansen J, Nielsen FC: RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J. 2006, 25: 1456-68. 10.1038/sj.emboj.7601039.CrossRefPubMedPubMedCentral

28.

Vainer G, Vainer-Mosse E, Pikarsky A, Shenoy SM, Oberman F, Yeffet A, Singer RH, Pikarsky E, Yisraeli JK: A role for VICKZ proteins in the progression of colorectal carcinomas: regulating lamellipodia formation. J Pathol. 2008, 215: 445-56. 10.1002/path.2376.CrossRefPubMedPubMedCentral

29.

Corcoran RB, Bachar Raveh T, Barakat MT, Lee EY, Scott MP: Insulin-like growth factor 2 is required for progression to advanced medulloblastoma in patched 1 heterozygous mice. Cancer Res. 2008, 68: 8788-95. 10.1158/0008-5472.CAN-08-2135.CrossRefPubMedPubMedCentral

30.

Kim KW, Bae SK, Lee OH, Bae MH, Lee MJ, Park BC: Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res. 1998, 58: 348-51.PubMed

31.

Björndahl M, Cao R, Nissen LJ, Clasper S, Johnson LA, Xue Y, Zhou Z, Jackson D, Hansen AJ, Cao Y: Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA. 2005, 102: 15593-8. 10.1073/pnas.0507865102.CrossRefPubMedPubMedCentral

32.

Csernus VJ, Schally AV, Kiaris H, Armatis P: Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci USA. 1999, 96: 3098-103. 10.1073/pnas.96.6.3098.CrossRefPubMedPubMedCentral

33.

Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, Halmos G: Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci USA. 1997, 94: 5810-3. 10.1073/pnas.94.11.5810.CrossRefPubMedPubMedCentral

34.

Lamharzi N, Schally AV, Koppán M, Groot K: Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. Proc Natl Acad Sci USA. 1998, 95: 8864-8. 10.1073/pnas.95.15.8864.CrossRefPubMedPubMedCentral

35.

Lamm GM, Christofori G: Impairment of survival factor function potentiates chemotherapy induced apoptosis in tumor cells. Cancer Res. 1998, 58: 8017-

36.

Wang T, Fan L, Watanabe Y, McNeill PD, Moulton GG, Bangur C, Fanger GR, Okada M, Inoue Y, Persing DH, Reed SG: L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer. 2003, 88: 887-94. 10.1038/sj.bjc.6600806.CrossRefPubMedPubMedCentral

37.

Nemunaitis J, Meyers T, Senzer N, Cunningham C, West H, Vallieres E, Anthony S, Vukelja S, Berman B, Tully H, Pappen B, Sarmiento S, Arzaga R, Duniho S, Engardt S, Meagher M, Cheever MA: Phase I Trial of sequential administration of recombinant DNA and adenovirus expression L523S protein in early stage non-small-cell lungcancer. Mol Ther. 2006, 13: 1185-91. 10.1016/j.ymthe.2006.01.013.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/59/prepub

Title: Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival
Authors: David F Schaeffer
Daniel R Owen
Howard J Lim
Andrew K Buczkowski
Stephen W Chung
Charles H Scudamore
David G Huntsman
Sylvia SW Ng
David A Owen
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-10-59

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Study Protocol: A randomized controlled trial of patient navigation-activation to reduce cancer health disparities

Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP

Interference with Activator Protein-2 transcription factors leads to induction of apoptosis and an increase in chemo- and radiation-sensitivity in breast cancer cells

Primary liposarcoma of the ascending colon: a rare case of mixed type presenting as hemoperitoneum combined with other type of retroperitoneal liposarcoma

Small RNA interference-mediated gene silencing of heparanase abolishes the invasion, metastasis and angiogenesis of gastric cancer cells

NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL

Keynote webinar | Spotlight on antibody–drug conjugates in cancer